

## Inflammatory Biomarkers Can Differentiate Acute Lymphoblastic Leukemia with Arthropathy from Juvenile Idiopathic Arthritis Better Than Standard Blood Tests

Brix, Ninna; Glerup, Mia; Foell, Dirk; Kessel, Christoph; Wittkowski, Helmut; Berntson, Lillemor; Fasth, Anders; Nielsen, Susan; Nordal, Ellen; Rygg, Marite; Hasle, Henrik; Herlin, Troels; Nordic Study Group of Pediatric Rheumatology (NoSPeR) group

*Published in:*  
The Journal of Pediatrics

*DOI (link to publication from Publisher):*  
[10.1016/j.jpeds.2023.113406](https://doi.org/10.1016/j.jpeds.2023.113406)

*Creative Commons License*  
CC BY 4.0

*Publication date:*  
2023

*Document Version*  
Publisher's PDF, also known as Version of record

[Link to publication from Aalborg University](#)

*Citation for published version (APA):*  
Brix, N., Glerup, M., Foell, D., Kessel, C., Wittkowski, H., Berntson, L., Fasth, A., Nielsen, S., Nordal, E., Rygg, M., Hasle, H., Herlin, T., & Nordic Study Group of Pediatric Rheumatology (NoSPeR) group (2023). Inflammatory Biomarkers Can Differentiate Acute Lymphoblastic Leukemia with Arthropathy from Juvenile Idiopathic Arthritis Better Than Standard Blood Tests. *The Journal of Pediatrics*, 258, Article 113406. <https://doi.org/10.1016/j.jpeds.2023.113406>

### General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal -

**Take down policy**

If you believe that this document breaches copyright please contact us at [vbn@aub.aau.dk](mailto:vbn@aub.aau.dk) providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from [vbn.aau.dk](http://vbn.aau.dk) on: July 04, 2025



# Inflammatory Biomarkers Can Differentiate Acute Lymphoblastic Leukemia with Arthropathy from Juvenile Idiopathic Arthritis Better Than Standard Blood Tests

Ninna Brix, MD, PhD<sup>1</sup>, Mia Glerup, MD, PhD<sup>2</sup>, Dirk Foell, MD, PhD<sup>3</sup>, Christoph Kessel, MD, PhD<sup>3</sup>, Helmut Wittkowski, MD<sup>3</sup>, Lillemor Berntson, MD, PhD<sup>4</sup>, Anders Fasth, MD, PhD<sup>5</sup>, Susan Nielsen, MD<sup>6</sup>, Ellen Nordal, MD<sup>7</sup>, Marite Rygg, MD, PhD<sup>8,9</sup>, Henrik Hasle, MD, PhD<sup>2</sup>, and Troels Herlin, MD, PhD<sup>2</sup>, and the Nordic Study Group of Pediatric Rheumatology (NoSPeR) group

**Objective** To evaluate the predictive value of biomarkers of inflammation like phagocyte-related S100 proteins and a panel of inflammatory cytokines in order to differentiate the child with acute lymphoblastic leukemia (ALL) from juvenile idiopathic arthritis (JIA).

**Study design** In this cross-sectional study, we measured S100A9, S100A12, and 14 cytokines in serum from children with ALL (n = 150, including 27 with arthropathy) and JIA (n = 236). We constructed predictive models computing areas under the curve (AUC) as well as predicted probabilities in order to differentiate ALL from JIA. Logistic regression was used for predictions of ALL risk, considering the markers as the respective exposures. We performed internal validation using repeated 10-fold cross-validation and recalibration, adjusted for age.

**Results** In ALL, the levels of S100A9, S100A12, interleukin (IL)-1 beta, IL-4, IL-13, IL-17, matrix metalloproteinase-3, and myeloperoxidase were low compared with JIA ( $P < .001$ ). IL-13 had an AUC of 100% (95% CI 100%-100%) due to no overlap between the serum levels in the 2 groups. Further, IL-4 and S100A9 had high predictive performance with AUCs of 99% (95% CI 97%-100%) and 98% (95% CI 94%-99%), respectively, exceeding both hemoglobin, platelets, C-reactive protein, and erythrocyte sedimentation rate.

**Conclusions** The biomarkers S100A9, IL-4, and IL-13 might be valuable markers to differentiate ALL from JIA. (*J Pediatr* 2023;258:113406).

Acute lymphoblastic leukemia (ALL) may be misdiagnosed as juvenile idiopathic arthritis (JIA) since a significant proportion of childhood leukemia presents with arthropathy often combined with few and less robust classical signs of leukemia.<sup>1-3</sup> ALL is the most common childhood neoplasia, with an approximate annual incidence of 40 per million in the Nordic countries.<sup>4</sup> Further, ALL is the type of malignant neoplasm most frequent associated with arthropathy (arthralgia and arthritis) at disease onset.<sup>5-9</sup> JIA is the most common chronic inflammatory joint disease in children, with an annual incidence of 15 per 100 000 children in the Nordic countries.<sup>10,11</sup> ALL with arthropathy is at high risk of being misdiagnosed as JIA with the risk of diagnostic delay.<sup>1,12,13</sup> Routine inflammatory markers such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) have obvious limitations to differentiate ALL from JIA.<sup>3,14</sup> Thus, in demand are sensitive and specific biomarkers that can be used to optimize the diagnostic process.

The phagocyte-related and proinflammatory S100A8/A9 and S100A12 proteins have been identified as important markers of inflammation in several conditions, including inflammatory arthritis.<sup>14-16</sup> S100A9 forms a heterocomplex with S100A8 (also called MRP8/14) and can be detected by monoclonal S100A9 antibodies as used in immunoassays for its measurement in feces or

From the <sup>1</sup>Department of Pediatrics and Adolescent Medicine, Aalborg University Hospital, Aalborg, Denmark; <sup>2</sup>Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark; <sup>3</sup>Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany; <sup>4</sup>Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden; <sup>5</sup>Department of Pediatrics, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; <sup>6</sup>Department of Pediatrics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; <sup>7</sup>Department of Pediatrics, University Hospital of North Norway, and Department of Clinical Medicine, UiT, The Arctic University of Norway, Tromsø, Norway; <sup>8</sup>Department of Clinical and Molecular Medicine, NTNU-Norwegian University of Science and Technology, Trondheim, Norway; and <sup>9</sup>Department of Pediatrics, St Olavs Hospital, Trondheim, Norway

This work was supported by Arvid Nilsson's under grant 1780631; Danish Childhood Cancer Foundation under grant 2017-1945 and grant 2020-6653; and Ølufgard Memorial Fund under grant 25734. No sponsors or funders (other than the named authors) played any role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The authors have no conflicts of interest to disclose.

0022-3476/© 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).  
<https://doi.org/10.1016/j.jpeds.2023.113406>

ALL	Acute lymphoblastic leukemia	JIA	Juvenile idiopathic arthritis
AUC	Area under the receiver operating characteristic curve	CCL-2 CRP ESR	Chemokine ligand 2 C-reactive protein Erythrocyte sedimentation rate
CD25	Interleukin-2 receptor alpha chain	IL	Interleukin
JADAS71 score	Juvenile Arthritis Disease Activity Score for 71 joints	MMP-3 MPO WBC	Matrix metalloproteinase-3 Myeloperoxidase White blood cell

blood. Several studies have investigated S100A8/9 proteins in JIA and revealed a correlation with disease activity.<sup>14,15,17-24</sup> In ALL, the evaluation of S100 proteins is very limited.<sup>22,25</sup> Cytokines are effector molecules for cells involved in the immune and inflammatory responses and the hematopoietic cell proliferation and differentiation.<sup>26-29</sup> In JIA, tumor necrosis factor- $\alpha$ , interleukins (ILs) IL-6, IL-10, IL-12, and IL-18 have been shown to correlate with disease activity.<sup>30-38</sup> IL-4 and IL-13 are critical components of Th2-cell-mediated immunity and recently have been described as important markers in the pathogenesis of inflammatory arthritis.<sup>39,40</sup> In rheumatoid arthritis, IL-4 and IL-13 have been proven to downregulate the inflammatory processes and correlate with disease activity.<sup>41-44</sup> In ALL, cytokines have been investigated only to a minimal extent in vitro and in small cohorts, mainly in adults.<sup>25,45-49</sup>

There exist 2 different clinical scenarios for physicians to consider regarding differentiating ALL and JIA. The first is the child with systemic JIA with the risk of being misdiagnosed as several systemic inflammatory diseases, such as systemic infections, macrophage-activating syndrome, and various types of cancers, one of them being ALL. This scenario has been the main focus of the literature, revealing S100A9, S100A12, and IL-18 as valuable biomarkers identifying systemic JIA.<sup>14,22,25</sup> The other scenario, which is the focus of this paper, is the child with ALL mistaken for nonsystemic JIA, which may delay ALL diagnosis.<sup>3,14</sup> Only a few studies have evaluated newer inflammatory biomarkers in order to optimize the diagnostic process and avoid ALL with arthropathy being misdiagnosed as JIA.<sup>50</sup> The primary aim of our study was to investigate the predictive value of biomarkers of inflammation to differentiate ALL from JIA in pediatric patients.

## Methods

We included consecutive cases of newly diagnosed patients with JIA from defined geographical areas of Denmark, Norway, and Sweden, as previously described in detail.<sup>51,52</sup> They had disease onset from January 1, 1997, to June 30, 2000. The Finnish portion of the original cohort had no access to storage of blood samples at baseline, and, accordingly, this center was not included in the present study. For the JIA cohort, the data were collected 6 months ( $-1/+$  2 months) after disease onset. The JIA serum samples were 1:4 prediluted in tris-buffered saline.

We further included consecutive, newly diagnosed children with ALL from a nonselected, population-based Danish ALL cohort, with inclusion from January 1, 2001, to December 31, 2018, from Aalborg and Aarhus University Hospitals, Denmark. For the ALL cohort, data were collected as close to diagnosis as possible ( $+/-$  1 week) and before anti-cancer therapy was initiated. All children included in the study had an established diagnosis of ALL or JIA at the time of inclusion. The diagnosis of ALL was based on bone marrow biopsy and the diagnosis of JIA according to the International League of Associations for Rheumatology

criteria for JIA.<sup>53</sup> Arthralgia was defined as pain distinctly localized to 1 or more joints. Arthritis was defined as swelling within a joint and/or limitation of joint motion with joint pain. Arthropathy was defined as arthralgia and/or arthritis.

The following data were collected in both cohorts: demographics (age, sex), clinical presentation (disease category, risk group, number of active and cumulative joints with arthritis), and clinical laboratory variables (hemoglobin, platelets, ESR, CRP). For the children with ALL, we also collected counts of white blood cells (WBCs), neutrophils, monocytes, lymphocytes, and blasts in peripheral blood. For the children with JIA, the Juvenile Arthritis Disease Activity Score for 71 joints (JADAS71 score) was used to evaluate disease activity.<sup>54</sup>

## Assays

Serum samples for biomarker analysis were stored at  $-80^{\circ}\text{C}$ . The serum concentrations of S100A9 (as a measurement of the S100A8/A9 complex), S100A12, IL-1 $\beta$ , IL-4, IL-6, IL-10, IL-12p70, IL-13, IL-17A, IL-18, tumor necrosis factor- $\alpha$ , matrix metalloproteinase 3 (MMP-3) and myeloperoxidase (MPO), chemokine ligand 2 (CCL-2), and soluble CD25 (CD25) were determined by multiplexed bead array assay according to the manufacturer's instructions (R&D Systems). Data acquisition and analysis were performed on a MAGPIX instrument (Merck Millipore) using xPONENT v4.2 software (Luminex). The analyzing laboratory in Muenster, Germany, was blinded to the patient's characteristics.

## Statistics

The concentrations of the biomarkers were non-normally distributed, as evaluated by QQ-plot and histograms. Therefore, the results were presented as median with first-third IQR and compared using the Mann-Whitney  $U$  test for continuous data and Fisher exact test for dichotomous variables. In addition, Spearman rank-order correlation was used to evaluate the correlation between the biomarkers, the laboratory values, and age.

In order to establish prediction models for ALL detection, we used logistic regression with fractional polynomials to handle nonlinearity in regressions. First, we performed univariate screening of potential predictors according to the outcome variable (ALL). For the best markers, we constructed logistic regression models, as we performed internal validation using repeated 10-fold cross-validation and recalibration, adjusted for age.<sup>55</sup> The performance of the models was evaluated using the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, positive predictive values, negative predictive values, and accuracy using a threshold of 0.5 for the predicted probabilities of ALL. Further, for the best markers, we identified optimal cut-offs from receiver operating characteristic analyses with the goal of a sensitivity of minimum 95% due to the severity of ALL.

We used Stata, version 17.0 (StataCorp) for all statistical analyses performed together with a professional statistician. Statistical significance was established at 5% for a 2-dimensional test.

## Ethics

The study was approved by the Medical Ethics Committee (1-10-72-206-19) and the Danish Data Protection Agency (1-16-02-214-16). The data and samples of the JIA cohort were further approved by the national research committees (1-10-72-280-13, 2012/2051, Dnr 2014/413-31, 174/13/03/03/2014), and all patients gave their written informed consent. For patients with ALL, serum samples were collected from the Nordic Society of Pediatric Oncology and Hematology biobank in Uppsala, and all patients gave their written informed consent.

## Results

Of 257 consecutive children diagnosed with ALL from 2001 to 2018, serum was available for biomarker analysis in 150 of 257 (58%) participants, who were included in the present study. The age at onset and subgroup distribution did not differ for the included group compared with those with no available serum. The ALL cohort included 123 of 150 (85%) pre-B cell ALL and 22 of 150 (15%) T-cell ALL. Arthropathy at presentation occurred in 18% (27/150), including 20/150 (13%) with arthralgia, and 7 of 150 (5%) with arthritis. The median number of joints involved was 2 (IQR 1-7, range 1-9). Arthropathy mainly occurred in the pre-B ALL group, present in 20% (26/128), whereas only 1 patient with T-cell ALL presented with arthralgia. In the group with T-cell ALL, we found higher levels of hemoglobin, platelets, neutrophils, S100A9, S100A12, and MPO, compared with the group with pre-B ALL. In contrast, the level of CCL-2 was lower in the group with T-cell ALL (Table I). Due to the risk of inhomogeneous results, we excluded the children with T-cell ALL from the analysis when comparing ALL<sub>arthropathy</sub> (n = 26) with the children without arthropathy (n = 102). The levels of hemoglobin, platelets, neutrophils, CRP, S100A9, S100A12, and MPO were higher in the group with ALL<sub>arthropathy</sub> compared with the patients without any arthropathy. In contrast, the levels of IL-10 were lower in the patients with pre-B ALL<sub>arthropathy</sub> compared with the patients without any arthropathy (Table II).

Of 510 consecutive children diagnosed with JIA from 1997 to 2000, serum for the biomarker analysis was available in 236 (46%), who were included in the present study. Age at onset, JIA categories, the number of active joints, or JADAS71 score did not differ for the included group compared with those with no available serum. The distribution of JIA categories was oligoarthritis 119 of 236 (50%), polyarticular rheumatoid factor-negative JIA 46 of 236 (19%), polyarticular rheumatoid factor-positive JIA 5 of 236 (2%), systemic JIA 11 of 236 (5%), enthesitis-related arthritis 219 of 236 (8%), juvenile psoriatic arthritis 2 of 236 (1%), and undifferentiated JIA 34 of 236 (14%). The median number of active joints was 1 (IQR 0-3, range 0-31), and the median number of cumulative joints was 3 (IQR 1-7, range 1-45). The JADAS71 score was 5 (IQR 2-11, range 0-43).

**Table I. Comparison of the protein levels for children with T-ALL vs pre-B-ALL**

Values	T-ALL n = 22	Pre-B-ALL n = 128	P value
Hemoglobin, g/dL	10 (8-12)	7.4 (5.3-9.5)	<.001
Platelets, × 10 <sup>9</sup> /L	58 (41-157)	43 (16-101)	.16
WBC, × 10 <sup>9</sup> /L	22 (5-86)	9 (4-41)	.09
Neutrophils, × 10 <sup>9</sup> /L	2.1 (0.4-4.9)	0.4 (0.2-1.0)	<.001
Monocytes, × 10 <sup>9</sup> /L	0.5 (0.2-2.0)	0.3 (0.1-1.1)	.16
Lymphocytes, × 10 <sup>9</sup> /L	4.6 (1.9-19)	5.6 (3.5-15)	.76
CRP, mg/L	14 (8-36)	21 (7-51)	.35
ESR, mm/H	47 (19-104)	68 (39-104)	.35
S100A9, pg/mL	124 (45-288)	40 (21-85)	<.001
S100A12, pg/mL	479 (221-1234)	78 (28-250)	<.001
TNF-alpha, pg/mL	11 (4-20)	7.6 (4.6-14.2)	.37
IL-1 beta, pg/mL	1.3 (1.2-1.9)	1.3 (1.1-2.3)	.74
IL-4, pg/mL	11 (9-15)	13 (10-16)	.08
IL-6, pg/mL	2.4 (1.5-3.4)	3.1 (1.8-6.3)	.13
IL-10, pg/mL	4.5 (1.0-11.5)	4.1 (1.8-9.8)	.91
IL-12p70, pg/mL	15 (7-23)	20 (10-26)	.28
IL-13, pg/mL	90 (79-97)	90 (79-97)	.60
IL-17, pg/mL	2.0 (0.2-2.0)	1.7 (1.1-2.0)	.75
IL-18, pg/mL	362 (138-618)	329 (218-557)	.71
MMP-3, pg/mL	1386 (1053-1998)	1360 (970-2553)	.92
MPO pg/mL	2450 (976-4361)	451 (187-1197)	<.001
CCL-2, pg/mL	276 (163-401)	359 (246-554)	.03
CD25, pg/mL	1000 (713-1322)	1155 (873-1643)	.16

B-ALL, B-cell acute lymphoblastic leukemia; CCL-2, chemokine ligand 2; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; IL, interleukin; MMP-3, matrix metalloproteinase 3; MPO, myeloperoxidase; T-ALL, T-cell acute lymphoblastic leukemia; TNF, tumor necrosis factor; WBC, white blood cells. Values are medians with IQRs.

In Table III, the clinical characteristics and the level of the biomarkers are compared for JIA (n = 236) vs ALL (n = 150) and ALL<sub>arthropathy</sub> (n = 27), respectively. Hemoglobin and platelets were low in both the total ALL cohort and the subgroup with ALL<sub>arthropathy</sub> compared with JIA, whereas CRP and ESR were greater in JIA than ALL (Table III). The levels of S100A9, S100A12, IL-1 beta, IL-4, IL-6, IL-13, IL-17, MMP-3, and MPO were low in ALL and ALL<sub>arthropathy</sub> compared with JIA. The levels of IL-13 had no overlap between the ALL (range 58-138 pg/mL) and the JIA group (range 256-2881). In contrast, IL-18, CCL-2, and CD25 levels were higher in ALL and ALL<sub>arthropathy</sub> compared with JIA (Table III). The same differences were found when comparing the patients with nonsystemic JIA (n = 225) with those with pre-B ALL (Table IV). The 11 patients with systemic JIA had very high levels of S100A9, S100A12, and IL-18. When comparing systemic JIA vs non-systemic JIA, we found significantly higher levels of S100A9 (P = .006), S100A12 (P = .007), and IL-18 (P < .001).

The associations between the 15 biomarkers and the standard blood tests are illustrated in heat plots for the ALL and JIA cohorts (Figures 1 and 2). In ALL, most biomarkers had strong positive correlations to CRP. In contrast, ESR was negatively correlated with S100A9, S100A12, and MPO. S100A9, S100A12, and MPO had strong positive correlations with circulating neutrophils and, to a smaller extent, with WBC and hemoglobin concentrations. The interactions between the biomarkers were evident with strong positive correlations. We highlight high positive

**Table II. Clinical characteristics and level of proteins in patients with ALL without arthropathy vs ALL with arthropathy**

Characteristics	Pre-B-ALL n = 102	Pre-B ALL <sub>arthropathy</sub> n = 26	P value
Female, No. (%) % (n/N)	42% (43/102)	65% (16/26)	.02
Standard risk, % (n/N)	51% (52/102)	30% (8/26)	.17
Intermediate risk, % (n/N)	27% (28/102)	35% (9/26)	.32
High risk, % (n/N)	22% (22/102)	23% (6/26)	.59
Blasts in peripheral blood, % (n/N)	75% (76/102)	50% (13/26)	.13
Age, y	4.3 (2.7-8.7)	5.6 (3.4-8.0)	.52
Hemoglobin, g/dL	7.1 (5.3-8.7)	9.5 (6.9-11.3)	.001
Platelets, × 10 <sup>9</sup> /L	39 (14-74)	117 (31-175)	.001
WBC, × 10 <sup>9</sup> /L	8.7 (3.8-39)	7.5 (2.7-18)	.35
Neutrophils, × 10 <sup>9</sup> /L	0.3 (0.1-0.7)	0.7 (0.3-1.4)	.02
Monocytes, × 10 <sup>9</sup> /L	0.3 (0.0-1.0)*	0.4 (0.1-2.6)	.46
Lymphocytes, × 10 <sup>9</sup> /L	5.6 (2.6-15)*	4.3 (2.4-11)	.41
CRP, mg/L	20 (7-46)*	51 (15-114)	.02
ESR, mm/H	82 (48-109)*	65 (38-91)†	.44
S100A9, pg/mL	37 (21-77)	51 (20-122)	.06
S100A12, pg/mL	67 (20-191)	216 (123-528)	<.001
TNF-alpha, pg/mL	7.3 (4.4-14)	10 (5.4-18)	.42
IL-1 beta, pg/mL	1.3 (1.1-2.3)	1.5 (0.8-2.3)	.88
IL-4, pg/mL	13 (10-16)	12 (10-14)	.26
IL-6, pg/mL	3.0 (1.8-6.0)	3.8 (1.5-6.5)	.79
IL-10, pg/mL	4.8 (2.0-12)*	2.4 (0.9-5.5)‡	.004
IL-12 p70, pg/mL	20 (10-26)	23 (13-26)	.46
IL-13, pg/mL	90 (79-99)	82 (74-97)	.40
IL-17, pg/mL	1.7 (1.1-2.0)*	1.1 (1.1-2.0)‡	.19
IL-18, pg/mL	353 (225-570)	287 (184-423)	.13
MMP-3, pg/mL	1351 (955-2390)	1366 (1060-2736)	.63
MPO, pg/mL	335 (170-963)	986 (292-3072)	.01
CCL-2, pg/mL	350 (247-558)	449 (185-549)	.75
CD25, pg/mL	1211 (920-1626)	1069 (724-1698)	.34

Values are expressed as median with IQR in parentheses unless otherwise stated.

\*Missing values, ALL: monocytes and lymphocytes n = 114; CRP: n = 112; ESR: n = 42; IL-10: n = 109; IL-17: n = 75.

†Missing values ALL<sub>arthropathy</sub>: ESR: n = 18; IL-10: n = 22; IL-17: n = 17.

**Table III. Comparison of the clinical characteristics with the level of the biomarkers in JIA (n = 236) vs ALL (n = 150) and JIA vs ALL<sub>arthropathy</sub> (n = 27)**

Characteristics	Normal ranges	JIA n = 236	All n = 150	P value	ALL <sub>arthropathy</sub> n = 27	P value
Females, No. (%)		166 (70)	67 (45)	<.001	18 (67)	.826
Age, y		6.0 (2.9-10.3)	4.6 (2.9-9.3)	.493	5.7 (3.6-9.5)	.959
Hemoglobin, g/dL		11.7 (11.3-12.8)*	7.9 (5.6-10.0)	<.001	9.7 (7.7-11.1)	<.001
Platelets, × 10 <sup>9</sup> /L		331 (287-415)*	48 (20-115)	<.001	144 (47-178)	<.001
CRP, mg/L		0 (0-10)*	21 (7-51)‡	<.001	33 (20-97)	<.001
ESR, mm/H		12 (6-24)*	65 (39-104)†	<.001	68 (39-99)	<.001
S100A9, pg/mL	471 (15-1771)	511 (315-1281)	44 (11-106)	<.001	47 (30-113)	<.001
S100A12, pg/mL	4419 (256-10917)	925 (434-1610)	106 (33-356)	<.001	221 (124-528)	<.001
TNF-alpha, pg/mL	3.5 (2.4-30)	9.1 (1.7-17)	8.2 (4.4-17)	.312	9.2 (5.4-18.1)	.312
IL-1 beta, pg/mL	4.6 (3.5-22)	17 (7-30)	1.3 (1.1-2.3)	<.001	1.5 (0.8-2.3)	<.001
IL-4, pg/mL	10.4 (2.7-11.4)	89 (55-133)	12 (10-16)	<.001	12 (10-14)	<.001
IL-6, pg/mL	17 (0.53-42)	6.4 (3.2-13)	2.9 (1.7-5.5)	<.001	3.8 (1.5-6.5)	.030
IL-10, pg/mL	3 (0.23-20)	5.3 (2.3-7.1)	4.4 (1.8-9.8)‡	.295	2.4 (1.1-5.7)‡	.130
IL-12 p70, pg/mL	*	13 (0.5-72)	20 (10-26)	.758	23 (13-26)	.940
IL-13, pg/mL	*	497 (387-621)	90 (79-97)	<.001	82 (79-97)	<.001
IL-17, pg/mL	3.6 (0.5-8.7)	9.7 (0.8-16)	1.6 (1.1-2.0)‡	<.001	1.1 (1.1-2.0)‡	<.001
IL-18, pg/mL	23 (3.5-489)	206 (136-292)	330 (213-557)	<.001	278 (146-423)	.040
MMP-3, pg/mL	3351 (11.2-8645)	5174 (1747-16460)	1360 (977-2528)	<.001	1415 (1050-2528)	<.001
MPO pg/mL	*	2289 (1593-3561)	569 (218-1568)	<.001	975 (292-1957)	<.001
CCL2, pg/mL	3.8 (5-19)	180 (112-251)	349 (234-543)	<.001	449 (185-549)	<.001
CD25, pg/mL	2324 (7.3-21918)	590 (421-766)*	1117 (824-1587)	<.001	1021 (724-1587)	<.001

Values are stated as median with IQR unless otherwise stated. P values are calculated by Mann-Whitney U test, except for categorical variables calculated by Fisher exact test (P\*).

\*Missing values, JIA: hemoglobin: n = 201; platelets: n = 203; CRP: n = 198, ESR: n = 196, CD25: n = 202.

†Missing values, ALL: CRP: n = 139; ESR: n = 58; IL-10: n = 131; IL-17: n = 92.

‡Missing values, ALL<sub>arthropathy</sub>: ESR: n = 18; IL-10: n = 22; IL-17: n = 17.

**Table IV.** Comparison of clinical characteristics and level of biomarkers between pre-B-ALL (n = 128) vs nonsystemic JIA (n = 225) and systemic JIA (n = 11)


Characteristics	Pre-B-ALL n = 128	Nonsystemic JIA n = 225	P value	Systemic JIA n = 11	P value
Female, No. (%)	59 (46)	158 (70)	<.001	7 (64)	.21
Age, y	4.3 (2.7-8.6)	6.5 (2.9-10.4)	<.001	4.7 (1.5-11.0)	.65
Hemoglobin, g/dL	7.4 (5.3-9.5)	11.9 (11.3-12.9) <sup>†</sup>	<.001	11.3 (9.7-11.4)	<.001
Platelets, × 10 <sup>9</sup> /L	43 (16-101)	330 (287-408) <sup>†</sup>	<.001	367 (206-756)	<.001
CRP, mg/L	9 (4-41)	0 (0-0) <sup>†</sup>	<.001	25 (10-62)	.98
ESR, mm/H	0.4 (0.2-1.0)	12 (6-22) <sup>†</sup>	<.001	28 (9-80)	.02
S100A9, pg/mL	40 (21-85)	508 (314-1087)	<.001	1403 (362-5381)	<.001
S100A12, pg/mL	78 (28-250)	904 (433-1605)	<.001	1845 (526-8256)	<.001
TNF-alpha, pg/mL	7.6 (4.6-14.2)	9.1 (2.3-17)	.60	2.0 (1-27)	.24
IL-1 beta, pg/mL	1.3 (1.1-2.3)	17 (6.2-30)	<.001	17 (12-30)	<.001
IL-4, pg/mL	13 (10-16)	89 (57-133)	<.001	94 (5-185)	.11
IL-6, pg/mL	3.1 (1.8-6.3)	6.5 (3.2-13)	<.001	6.3 (2.1-39)	.08
IL-10, pg/mL	4.1 (1.8-9.8)	5.3 (2.3-7.1)	.37	6.4 (3.4-10.4)	.75
IL-12 p70, pg/mL	20 (10-26)	13 (0.5-72)	.70	28 (0.5-94)	.60
IL-13, pg/mL	90 (79-97)	497 (387-621)	<.001	546 (461-678)	<.001
IL-17, pg/mL	1.7 (1.1-2.0)	9.2 (0.8-16)	<.001	16 (0.8-35)	.005
IL-18, pg/mL	329 (218-557)	200 (136-276)	<.001	2046 (315-6721)	.005
MMP-3, pg/mL	1360 (970-2553)	5119 (1712-16389)	<.001	10 296 (2557-60797)	<.001
MPO pg/mL	451 (187-1197)	2286 (1534-3505)	<.001	2392 (1973-4659)	<.001
CCL-2, pg/mL	359 (246-554)	183 (112-255)	<.001	149 (60-184)	<.001
CD25*, pg/mL	1155 (873-1643)	588 (419-766) <sup>†</sup>	<.001	660 (441-883)	<.001

\*Missing values ALL: CRP: n = 139; ESR: n = 58; IL-10: n = 131; IL-17: n = 92.


†Missing values JIA: hemoglobin: n = 192; platelets: n = 191; CRP: n = 186, ESR: n = 184, CD25: n = 191.

correlation between IL-1 beta, IL-4, IL-12p70, IL-13, IL-17, and MMP-3 (correlation coefficients 0.4-0.8,  $P < .001$ ). Further, S100A9, S100A12, and platelets had a strong positive correlation with MPO (correlation coefficients 0.4-0.6,  $P < .001$ ), **Figure 1**. The correlations did not differ for pre-B-cell ALL and T-cell ALL. In JIA, the correlations were less prominent, although the same

trends occurred (**Figure 2**). We found no significant correlation between active or cumulative joints and the biomarkers in ALL or JIA. For the JADAS71 score, we found weak positive correlations between S100A12, IL-4, IL-12p70, and IL-13 (correlation coefficients 0.19-0.25). The correlations did not differ for systemic and nonsystemic JIA.




**Figure 1.** Heat plot illustrating the correlations between age, laboratory values, and the biomarkers evaluated by Spearman correlation coefficient (c) for the acute lymphoblastic leukemia cohort (n = 150).



**Figure 2.** Heat plot illustrating the correlations between age, laboratory values, and the biomarkers evaluated by Spearman correlation coefficient (c) in the cohort with juvenile idiopathic arthritis (n = 236).

As the focus of this study is the child with ALL mistaken for nonsystemic JIA, and since the level of the biomarkers differed for both T-cell ALL vs pre-B-cell ALL and for systemic vs nonsystemic JIA (Table I), we excluded the 22 children with T-cell ALL (including just one with arthralgia) and the 11 children with systemic JIA from the predictive analyses. First, we calculated the cross-validated, recalibrated, and age-adjusted AUC values on the individual performance for each of the biomarkers. Then, for the best markers, we evaluated the predictive performance with optimal cut-off values

illustrated with AUCs and predicted probabilities (Figure 3 and Table V). For IL-13, there was no overlap in the serum levels for ALL and JIA resulting in an AUC of 100% (95% CI 100%-100%). Further, IL-4 and S100A9 had a high predictive performance with AUCs of respectively 99% (95% CI 97%-100%) and 98% (95% CI 94%-99%), Figure 3. The predictive performance of IL-4, IL-13, and S100A9 exceeded the predictive performance of both hemoglobin, platelets, CRP, and ESR (Table V). Further, S100A12, IL-1beta, IL-12p70, and CD-25 revealed high AUCs of 86-90%, although



**Figure 3.** Receiver operating characteristics curves illustrating the AUC model for the prediction of ALL.

**Table V.** The predictive performance of the best biomarkers compared with the existing laboratory values (hemoglobin, platelets, CRP, and ESR) to detect pre-B-ALL (n = 128, hereof 26 with arthropathy) from nonsystemic JIA (n = 225)

Biomarkers	Optimal cut-off	AUC (95% CI)	Accuracy (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	PPV (95% CI)	NPV (95% CI)
IL-13	<140 pg/mL	100% (100%-100%)	100% (100%-100%)	100% (100%-100%)	100% (100%-100%)	100% (100%-100%)	100% (100%-100%)
IL-4	<23 pg/mL	99% (97%-100%)	97% (95%-99%)	99% (96%-100%)	95% (89%-98%)	97% (94%-99%)	98% (93%-100%)
S100A9	<230 pg/mL	98% (94%-99%)	93% (89%-96%)	95% (90%-97%)	91% (84%-95%)	93% (89%-97%)	92% (86%-96%)
Platelets	<278 × 10 <sup>9</sup> /L	97% (92%-98%)	96% (93%-98%)	98% (95%-99%)	92% (86%-96%)	95% (91%-98%)	97% (92%-99%)
Hemoglobin	<12 g/dL	93% (88%-96%)	89% (85%-93%)	94% (90%-97%)	82% (74%-88%)	89% (83%-93%)	90% (84%-95%)
ESR	>15 mm/H	92% (83%-94%)	87% (82%-91%)	93% (88%-96%)	60% (46%-75%)	91% (86%-94%)	68% (51%-82%)
IL-1 beta	<4 pg/mL	90% (85%-92%)	79% (74%-84%)	71% (64%-78%)	90% (83%-94%)	90% (84%-95%)	70% (62%-77%)
S100A12	<864 pg/mL	89% (85%-93%)	83% (78%-87%)	86% (81%-91%)	77% (68%-84%)	86% (81%-91%)	77% (68%-84%)
IL-12p70	>36 pg/mL	88% (83%-91%)	79% (74%-83%)	83% (78%-88%)	71% (62%-79%)	83% (78%-88%)	71% (62%-79%)
CRP	>1 mg/L	87% (79%-89%)	77% (72%-82%)	84% (78%-89%)	65% (55%-74%)	81% (75%-86%)	69% (59%-78%)
CD-25	>458 pg/mL	86% (80%-90%)	81% (76%-85%)	90% (84%-94%)	68% (59%-76%)	81% (75%-86%)	81% (72%-88%)

NPV, negative predictive value; PPV, positive predictive value.

Estimated from 10-fold cross validation, which has been recalibrated and computed using a threshold of 0.5 for the predicted probabilities of ALL.

with relatively low specificities and negative predictive values, which was also the case for ESR and CRP (Figure 3 and Table V). Finally, when simply calculating the sensitivity and specificity of IL-13 being below 140 for the 26 children with pre-B-cell ALL vs nonsystemic JIA, such revealed a sensitivity of 100% (95% CI 87%-100%) and a specificity of 100% (95% CI 98%-100%).

## Discussion

The value of inflammatory biomarkers as diagnostic tools to differentiate the child with ALL and arthropathy from the one with nonsystemic JIA has previously been evaluated to a very limited extent.<sup>50</sup> To advance understanding of the utility of inflammatory biomarkers, our study evaluated and identified S100A9, IL-4, and IL-13 as well-performing diagnostic markers, with AUC and predicted values exceeding both platelets, hemoglobin, CRP, and ESR. Recently, we evaluated the use of lectin complement pathway proteins as markers to differentiate ALL with arthropathy from JIA in the present cohort. We revealed M-ficolin as a valuable marker with an AUC of 94% (95% CI 83%-100%), exceeding CRP and hemoglobin.<sup>50</sup> In the present study, the AUCs for S100A9, IL-4, and IL-13 were 95%-100%, including high accuracies ranging from 93% to 100%, which indicates even higher diagnostic values than M-ficolin.

Identifying the child with ALL and arthropathy from JIA is challenging when hematological indices are close to normal and in the absence of blasts in peripheral blood.<sup>2,3</sup> Children with ALL and arthropathy present with few clinical and laboratory signs of leukemia compared with ALL without arthropathy,<sup>1</sup> and we confirmed higher levels of hemoglobin, platelets, and neutrophils in this subgroup. The levels of the biomarkers were equally low whether or not the child had arthropathy or blasts in peripheral blood, strengthening the diagnostic value.

The levels of the proinflammatory proteins S100A9 and S100A12 were higher in the subgroup with ALL<sub>arthropathy</sub> compared with ALL without arthropathy in the present study,

which is in accordance with previous findings of S100A9 and S100A12 as important markers of the inflammatory process in arthritis.<sup>14,15,22,56</sup> These phagocyte-specific S100 proteins are expressed in the cytoplasm of granulocytes and early stages of monocytes and can operate as strong pro-inflammatory cytokine-like molecules as do endogenous ligands of Toll-like receptor 4, when released from stressed or damaged cells.<sup>16,57,58</sup> Several studies have found S100AA9 and S100A12 elevated in JIA compared with healthy controls,<sup>17-20,23,24</sup> which we confirmed. Furthermore, we revealed low levels of S100A9 and S100A12 in ALL being low compared with the normal ranges and markedly lower than in JIA.

IL-4 and IL-13 have multiple functions, including regulating Th2-mediated immunity, stimulating B-cell proliferation, and activating eosinophils, basophils, and mast cells.<sup>40,59,60</sup> IL-4 and IL-13 have been stated as important elements of the pathogenesis of rheumatoid arthritis,<sup>39,40</sup> and have been suggested to play a significant role in the downregulation of the inflammatory process and beneficially modulate the course of the disease.<sup>41-44</sup> Spadaro et al found serum levels of IL-13 to be significantly higher in patients with rheumatoid arthritis than in healthy individuals.<sup>61</sup> We found high levels of IL-4 and IL-13 in children with JIA compared with children with ALL.

Functionally, cytokines have been classified as either proinflammatory or anti-inflammatory.<sup>29</sup> However, the specific role of individual cytokines during inflammation or injury can shift from beneficial to harmful depending on the nature of the pathologic state in which a cytokine is involved and its target cell population.<sup>29,62</sup> Further, cytokine-cytokine interactions play a crucial role during immunological and inflammatory responses resulting in additive, antagonistic, or synergistic activities.<sup>62,63</sup> We found high correlations between many of the cytokines, and as the correlation coefficients were above 0.7 among 2 or more predictors, there might be an element of collinearity as illustrated in the heat plots, which complicates the possible use of these markers as individual predictors.

Systemic JIA is an aggressive autoinflammatory disorder with extensive activation of the innate immune system, likely influenced by an imbalance between proinflammatory cytokines and immune deactivators.<sup>14,58,64</sup> Presentation of systemic JIA may be bewildering with many differential diagnoses due to clinical characteristics involving fever, affected hematologic parameters, enlargement of the liver and spleen, and rash.<sup>64</sup> In the present study, we found significantly higher levels of S100A9, S100A12, and IL-18 in systemic vs nonsystemic JIA, which is in accordance with previous findings.<sup>65,66</sup> These three markers have been suggested as valuable predictors to distinguish the child with systemic JIA from groups of other diseases that can be easily misdiagnosed as systemic JIA, here among ALL.<sup>14,22,25</sup>

There are some limitations to the study design and the analytic setup, which may have influenced the protein levels and conceivably impaired the predictive abilities. The first issue is the element of missing data. The number of patients with unavailable serum samples entails a risk of selection bias in both cohorts and reduced generalizability. In addition, the fact that we did not have any data on WBC or neutrophils in the JIA cohort is an important limitation, as neutrophils especially have been identified as a valuable marker to differentiate ALL from JIA.<sup>3,67</sup> Second, the JIA serum samples were collected up to 6 months after disease onset, with some patients being on disease-modifying antirheumatic drugs and having an inactive disease. However, the results show that most inflammatory markers were still higher in JIA than in ALL (and presumably would even be higher in untreated, active JIA), thereby implying a risk of underestimating the difference between the groups. Third, analyzing cohorts of patients with rare diseases is associated with some limitations regarding the interpretation of data due to the relatively low number of individual patients in subgroup analysis. Only 7 children had arthritis in the group of children with ALL, and only 11 had systemic JIA. Fourth, the level of the biomarkers might have been influenced by both a long storage period and the dilution of the serum samples for the JIA cohort. These issues may have influenced the protein levels and conceivably impaired their predictive abilities.<sup>68,69</sup> Finally, the predictive performance of S100A9, IL-4, and IL-13 should be repeated in another nonselected cohort, including external validation, to ensure that the diagnostic performance is reproducible. External validation in future studies would ensure that the diagnostic performance of S100A9, IL-4, and IL-13 is reproducible, ultimately evaluated in clinical trials before final conclusions can be drawn and before implementations in clinical practice would be recommended.

In conclusion, our results indicate that S100A9, IL-4, and IL-13 may be used as serum markers to distinguish pre-B-cell ALL from nonsystemic JIA. However, our prediction models require validation, repeating the study in another nonselected cohort. ■

*We acknowledge Jane Knudsen, Department of Pediatric and Adolescent Medicine, Aarhus University Hospital for handling the serum*

*samples. We also acknowledge the NOPHO Leukemia BioBank for providing serum samples.*

Submitted for publication Jan 23, 2023; last revision received Mar 21, 2023; accepted Mar 26, 2023.

Reprint requests: Ninna Brix, MD, PhD, Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, 8200, Aarhus, Denmark. E-mail: [ninna.brix@rn.dk](mailto:ninna.brix@rn.dk)

## References

- Brix N, Rosthøj S, Herlin T, Hasle H. Arthritis as presenting manifestation of acute lymphoblastic leukaemia in children. *Arch Dis Child* 2015;100:821-5.
- Jones O, Spencer C, Bowyer S, Dent P, Gottlieb B, Rabinovich C. A multicenter case-control study on predictive factors distinguishing childhood leukemia from juvenile rheumatoid arthritis. *Pediatrics* 2006;117:e840-4.
- Brix N, Rosthøj S, Glerup M, Hasle H, Herlin T. Identifying acute lymphoblastic leukemia mimicking juvenile idiopathic arthritis in children. *PLoS One* 2020;15:1-9.
- Hjalgrim L, Rostgaard K, Schmiegelow K, Söderhäll S, Kolmannskog S, Gustafsson G, et al. Age- and sex-specific incidence of childhood leukemia by immunophenotype in the Nordic countries. *J Nat Cancer Inst* 2003;95:1539-44.
- Robazzi T, Barreto J, Silva L, Mendonca N. Osteoarticular manifestations as initial presentation of acute leukemias in children and adolescents in Bahia, Brazil. *J Pediatr Hematol Oncol* 2007;29:622-6.
- Jonsson O, Sartain P, Ducore JM, Buchanan G. Bone pain as an initial symptom of childhood acute lymphoblastic leukemia: association with nearly normal hematologic indexes. *J Pediatr* 1990;117:233-7.
- Cabral D, Tucker L. Malignancies in children who initially present with rheumatic complaints. *J Pediatr* 1999;134:53-7.
- Menon S, Isenberg DA. Rheumatological manifestations of haematological diseases. *Ann Rheum Dis* 1995;54:787-95.
- Barbosa C, Nakamura C, Terreri M, Lee M, Petrilli A, Hilário M. Musculoskeletal manifestations as the onset of acute leukemias in childhood. *J Pediatr (Rio J)* 2002;78:481-4 [in Portuguese].
- Riise Ø, Handeland K, Cvancarova M, Wathne K-O, Nakstad B, Abrahamsen TG, et al. Incidence and characteristics of arthritis on Norwegian children: a population-based study. *Pediatrics* 2008;121:299-306.
- Berntson L, Andersson Gäre B, Fasth A, Herlin T, Kristinsson J, Lahdenne P, et al. Incidence of juvenile idiopathic arthritis in the Nordic countries. A population based study with special reference to the validity of the ILAR and EULAR criteria. *J Rheumatol* 2003;30:2271-82.
- Marwaha R, Kulkarni K, Bansal D, Trehan A. Acute lymphoblastic leukemia masquerading as juvenile rheumatoid arthritis: diagnostic pitfall and association with survival. *Ann Hematol* 2010;89:249-54.
- Sinigaglia R, Gigante C, Bisinella G, Varotto S, Zanesco L, Turra S. Musculoskeletal manifestations in pediatric acute leukemia. *J Pediatr Orthop* 2008;28:20-8.
- Frosch M, Ahlmann M, Vogl T, Wittkowski H, Wulffraat N, Foell D, et al. The myeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor 4, and interleukin-1 $\beta$  form a positive feedback mechanism in systemic-onset juvenile idiopathic arthritis. *Arthritis Rheum* 2009;60:883-91.
- Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. *Arthritis Rheum* 2004;50:3762-71.
- Foell D, Wittkowski H, Kessel C, Lüken A, Weinhage T, Varga G, et al. Proinflammatory S100A12 can activate human monocytes via toll-like receptor 4. *Am J Respir Crit Care Med* 2013;187:1324-34.
- Frosch M, Strey A, Sunderkotter C, Wittkowski H, Wulffraat N, Foell D, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers of monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. *Arthritis Rheum* 2000;43:628-37.

18. Berntzen H, Fagerhol M, Ostensen M, Mowinckel P, Hoyeraal H. The L1 protein as a new indicator of inflammatory activity in patient with juvenile rheumatoid arthritis. *J Rheumatol* 1991;18:133-8.
19. Frosch M, Vogl T, Seeliger S, Wulffraat N, Kuis W, Viemann D, et al. Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. *Arthritis Rheum* 2003;48:2622-6.
20. Foell D, Wittkowski H, Hammerschmidt I, Wulffraat N, Schmeling H, Frosch M, et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. *Arthritis Rheum* 2004;50:1286-95.
21. Foell D, Wulffraat N, Wedderburn L, Wittkowski H, Frosch M, Gerss J, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission. A randomized clinical trial. *JAMA* 2010;303.
22. Wittkowski H, Frosch M, Wulffraat N, Goldbach-Mansky R, Kallinich T, Kuemmerle-Dechner J, et al. S100A12 is a novel molecular marker differentiating systemic-onset juvenile idiopathic arthritis from other causes of fever of unknown origin. *Arthritis Rheum* 2008;58:3924-31.
23. Foell D, Frosch M, Schulza zur Wiesch A, Vogl T, Sorg C, Roth J. Methotrexate treatment in juvenile idiopathic arthritis: when is the right time to stop? *Ann Rheum Dis* 2004;63:206-8.
24. Wulffraat NM, Haas PJP, Brinkmann D, Frosch M, de Kleer IM, Vogl T, et al. Myeloid related protein 8 and 14 secretion reflects phagocyte activation and correlates with disease activity in juvenile idiopathic arthritis treated with autologous stem cell transplantation. *Ann Rheum Dis* 2003;62:236-41.
25. Xia Y, Cui P, Li Q, Liang F, Li C, Yang J. Extremely elevated IL-18 levels may help distinguish systemic-onset juvenile idiopathic arthritis from other febrile diseases. *Brazilian J Med Biol Res* 2017;50:1-7.
26. Shin GS, Lee BH, Lee S, Chung SY, Kim M, Lim J, et al. Monokine levels in cancer and infection. *Ann Clin Lab Sci* 2003;33:149-55.
27. Van Etten RA. Aberrant cytokine signaling in leukemia. *Oncogene* 2007;26:6738-49.
28. Woo P. Cytokines and juvenile idiopathic arthritis. *Curr Rheumatol Rep* 2002;4:452-7.
29. Cavaillon J. Pro- versus anti-inflammatory cytokines: myth or reality? *Cell Mol Biol* 2001;47.
30. Gattorno M, Picco P, Vignola S, Stalla F, Buoncompagni A, Pistoia V. Serum interleukin 12 concentration in juvenile chronic arthritis. *Ann Rheum Dis* 1998;57:425-8.
31. Mangge H, Kenzian H, Gallistl S, Neuwirth G, Liebmann P, Kaulfersch W, et al. Serum cytokines in juvenile rheumatoid arthritis: correlation with conventional inflammation parameters and clinical subtypes. *Arthritis Rheum* 1995;38:211-20.
32. Gattorno M, Picco P, Buoncompagni A, Stalla F, Facchetti P, Sormani MP, et al. Serum p55 and p75 tumour necrosis factor receptors as markers of disease activity in juvenile chronic arthritis. *Ann Rheum Dis* 1996;55:243-7.
33. Rezaei E, Hogan D, Trost B, Kusalik AJ, Boire G, Cabral DA, et al. Clinical and associated inflammatory biomarker features predictive of short-term outcomes in non-systemic juvenile idiopathic arthritis. *Rheumatology* 2020;59:2402-11.
34. Bojko JJ, Omelczenko LI, Czernyszow WP. Predictors of juvenile idiopathic arthritis course. *Reumatologia* 2015;53:119-24.
35. Yilmaz M, Kendirli SG, Altintas D, Bingöl G, Antmen B. Cytokine levels in serum of patients with juvenile rheumatoid arthritis. *Clin Rheumatol* 2001;20:30-5.
36. Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC, et al. Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. *Lancet Haematol* 2017;4:e202-17.
37. Mizuta M, Shimizu M, Inoue N, Ikawa Y, Nakagishi Y, Yachie A, et al. Clinical significance of interleukin-18 for the diagnosis and prediction of disease course in systemic juvenile idiopathic arthritis. *Rheumatology* 2021;60:2421-6.
38. Gohar F, Kessel C, Lavric M, Holzinger D, Foell D. Review of biomarkers in systemic juvenile idiopathic arthritis: helpful tools or just playing tricks? *Arthritis Res Ther [Internet]* 2016;18:1-12.
39. Chen Z, Bozec A, Ramming A, Schett G. Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis. *Nat Rev Rheumatol* 2019;15:9-17.
40. Iwaszko M, Biały S, Bogunia-Kubik K. Significance of interleukin (IL)-4 and IL-13 in inflammatory arthritis. *Cells* 2021;10:3000.
41. Siloși I, Boldeanu MV, Cojocaru M, Biciușcă V, Pădureanu V, Bogdan M, et al. The relationship of cytokines IL-13 and IL-17 with autoantibodies profile in early rheumatoid arthritis. *J Immunol Res* 2016;2016:3109135.
42. Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, et al. Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin. *Arthritis Res Ther* 2005;7:R784-95.
43. Kawashima M, Miossec P. mRNA quantification of T-bet, GATA-3, IFN-gamma, and IL-4 shows a defective Th1 immune response in the peripheral blood from rheumatoid arthritis patients: link with disease activity. *J Clin Immunol* 2005;25:209-14.
44. Bahlas S, Damiani L, Dandachi N, Sait H, Alsefri M, Pushparaj PN. Rapid immunoprofiling of cytokines, chemokines and growth factors in patients with active rheumatoid arthritis using Luminex Multiple Analyte Profiling technology for precision medicine. *Clin Exp Rheumatol* 2019;37:112-9.
45. Komada Y, Sakurai M. Cytokines and cytokine receptors in acute lymphoblastic leukemia expressing myeloid markers-role in growth regulation. *Leuk Lymphoma* 1994;15:411-8.
46. Horacek JM, Kupsa T, Vasatova M, Jebavy L, Zak P. Serum cytokine and adhesion molecule profile differs in newly diagnosed acute myeloid and lymphoblastic leukemia. *Biomed Pap* 2015;159:299-301.
47. Park HH, Kim M, Lee BH, Lim J, Kim Y, Lee EJ, et al. Intracellular IL-4, IL-10, and IFN- $\gamma$  levels of leukemic cells and bone marrow T cells in acute leukemia. *Ann Clin Lab Sci* 2006;36:7-15.
48. Bruserud O, Bergheim J, Shammass FV, Nesthus I. Serum concentrations of tumour necrosis factor- $\alpha$  during chemotherapy-induced leukopenia in patients with acute leukemia and bacterial-infections. *Leuk Res* 1994;18:415-21.
49. Bruserud Ø, Halstensen A, Peen E, Solberg CO. Serum levels of adhesion molecules and cytokines in patients with acute leukaemia. *Leuk Lymphoma* 1996;23:423-30.
50. Brix N, Glerup M, Thiel S, Mistegaard C, Gyldenholm R, Herlin T, et al. M-ficolin: a valuable biomarker to identify leukemia from juvenile idiopathic arthritis. *Arch Dis Child* 2022;107:371-6.
51. Glerup M, Thiel S, Rypdal V, Arnstad ED, Ekelund M, Peltoniemi S, et al. Complement lectin pathway protein levels reflect disease activity in juvenile idiopathic arthritis: a longitudinal study of the Nordic JIA cohort. *Pediatr Rheumatol Online J* 2019;17:63.
52. Glerup M, Rypdal V, Arnstad ED, Ekelund M, Peltoniemi S, Aalto K, et al. Long-term outcomes in juvenile idiopathic arthritis: eighteen years of follow-up in the population-based Nordic Juvenile Idiopathic Arthritis Cohort. *Arthritis Care Res (Hoboken)* 2019;72:507-16.
53. Petty R, Southwood T, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis. *J Rheumatol* 2004;31:390-2.
54. Consolaro A, Ruperto N, Balsa A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. *Arthritis Rheum* 2009;61:658-66.
55. Steyerberg EW, Vergouwe Y. Towards better clinical prediction models: seven steps for development and an ABCD for validation. *Eur Heart J* 2014;35:1925-31.
56. Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. *Gut* 2003;52:847-53.
57. Kessel C, Fuehner S, Zell J, Zimmermann B, Drewianka S, Brockmeyer S, et al. Calcium and zinc tune autoinflammatory Toll-like receptor 4 signaling by S100A12. *J Allergy Clin Immunol* 2018;142:1370-3.e8.

58. Kessel C, Holzinger D, Foell D. Phagocyte-derived S100 proteins in autoinflammation: putative role in pathogenesis and usefulness as biomarkers. *Clin Immunol* 2013;147:229-41.
59. Punnonen J, de Vries JE. IL-13 induces proliferation, Ig isotype switching, and Ig synthesis by immature human fetal B cells. *J Immunol* 1994;152:1094-102.
60. Defrance T, Vandervliet B, Aubry J, Takebe Y, Arai N, Banchereau J, et al. B cell growth-promoting activity of recombinant human interleukin 4. *J Immunol* 1987;139:1135.
61. Spadaro A, Rinaldi T, Riccieri V, Valesini G, Taccari E. Interleukin 13 in synovial fluid and serum of patients with psoriatic arthritis. *Ann Rheum Dis* 2002;61:174-6.
62. Meager T. Overview (a) Cytokine action (b) in vivo properties of cytokines (c) Cytokines and pathology (d). In: James K, Morris A, eds. *The molecular biology of cytokines*, 1-21 (a), 111-140 (b), 181-214 (c). New York: John Wiley & Sons; 1998. p. 215-36.
63. Souba W. Cytokine control of nutrition and metabolism in critical illness. *Curr Probl Surg* 1994;31:579-643.
64. Kessel C, Hedrich CM, Foell D. Innately adaptive or truly autoimmune: is there something unique about systemic juvenile idiopathic arthritis? *Arthritis Rheumatol* 2020;72:210-9.
65. De Jager W, Hoppenreijns EPAH, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. *Ann Rheum Dis* 2007;66:589-98.
66. Maenon N, Takei S, Nomura Y, Imanaka H, Hokonohara M, Miyata K. Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease: comment on the article by Kawashima et al. *Arthritis Rheum* 2002;46:2539-41.
67. Agodi A, Barchitta M, Trigilia C, Barone P, Marino S, Garozzo R, et al. Neutrophil counts distinguish between malignancy and arthritis in children with musculoskeletal pain: a case-control study. *BMC Pediatr* 2013;13:15.
68. Park C, Miranda-Garcia M, Berendes R, Horneff G, Kuemmerle-Deschner J, Ganser G, et al. MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever. *Rheumatology (Oxford)* 2022;61:3082-92.
69. De Jager W, Bourcier K, Rijkers GT, Prakken BJ, Seyfert-Margolis V. Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. *BMC Immunol* 2009;10:52.